Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK et al..  2018.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184-191.

Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, Pentelute BL, Agar NYR, Cho C-F.  2018.  Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.. Nat Protoc. 13(12):2827-2843.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.  2018.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.

Juliano J, Gil O, Hawkins-Daarud A, Noticewala S, Rockne RC, Gallaher J, Massey SC, Sims PA, Anderson ARA, Swanson KR et al..  2018.  Comparative dynamics of microglial and glioma cell motility at the infiltrative margin of brain tumours.. J R Soc Interface. 15(139)

Rayfield CA, Grady F, De Leon G, Rockne R, Carrasco E, Jackson P, Vora M, Johnston SK, Hawkins-Daarud A, Clark-Swanson KR et al..  2018.  Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.. JCO Clin Cancer Inform. 2:1-14.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F et al..  2018.  Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.. Mol Cancer Ther. 17(9):1893-1901.

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC et al..  2018.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.. Mol Cancer Res.

Basu SS, Randall EC, Regan MS, Lopez BGC, Clark AR, Schmitt ND, Agar JN, Dillon DA, Agar NYR.  2018.  In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture.. Anal Chem. 90(8):4987-4991.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL et al..  2018.  Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.. Nat Commun. 9(1):4904.

Prahl LS, Bangasser PF, Stopfer LE, Hemmat M, White FM, Rosenfeld SS, Odde DJ.  2018.  Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration.. Cell Rep. 25(9):2591-2604.e8.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.  2018.  Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.. J Pharmacol Exp Ther. 365(2):249-261.

Rothenberg DA, J Taliaferro M, Huber SM, Begley TJ, Dedon PC, White FM.  2018.  A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth.. iScience. 9:367-381.

Emdal KB, Dittmann A, Reddy RJ, Lescarbeau RS, Moores SL, Laquerre S, White FM.  2017.  Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.. Mol Cancer Ther. 16(11):2572-2585.

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.  2017.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 123:10-25.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN et al..  2017.  Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.. J Pharmacol Exp Ther. 363(2):136-147.

Li MJun, Yao H, Huang D, Liu H, Liu Z, Xu H, Qin Y, Prinz J, Xia W, Wang P et al..  2017.  mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers.. Nucleic Acids Res. 45(W1):W215-W221.